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Bacteriocins, a heterogenous group of antibacterial ribosomally synthesized peptides,
have potential as bio-preservatives in in a wide range of foods and as future therapeutics
for the inhibition of antibiotic-resistant bacteria. While many bacteriocins have been
characterized, several factors limit their production in large quantities, a requirement to
make them commercially viable for food or pharma applications. The identification of
new bacteriocins by database mining has been promising, but their potential is difficult
to evaluate in the absence of suitable expression systems. E. coli has been used as a
heterologous host to produce recombinant proteins for decades and has an extensive
set of expression vectors and strains available. Here, we review the different expression
systems for bacteriocin production using this host and identify the most important
features to guarantee successful production of a range of bacteriocins.
Keywords: bacteriocins, heterologous expression, E. coli, vectors, strains
INTRODUCTION
Bacteriocins are antimicrobial peptides produced by Gram-negative and Gram-positive bacteria.
These molecules have attracted considerable interest, especially those produced by GRAS
(Generally Recognized As Safe) microorganisms, as natural food preservatives in the food industry.
They also represent potential alternatives to traditional antibiotics in the treatment of infections in
humans and food-producing animals (Cotter et al., 2005; Desriac et al., 2010; Svetoch and Stern,
2010) and, in some cases, show promise as drugs for cancer treatment (reviewed in Kaur and Kaur,
2015).
Since the identification of colicin in 1925 (Gratia, 1925), many bacteriocins have been
described (BAGEL4 database, http://bagel4.molgenrug.nl). However, only nisin (e.g., Nisaplin R©)
and pediocin PA-1 (e.g., ALTA R©-2431) have been commercialized to any significant extent and
these mainly as food biopreservatives. This may be explained by the multitude of studies that are
required before a bacteriocin can be considered commercially viable, including characterization,
potent antimicrobial activity, product stability, mechanism of action, mode of delivery, toxicity
and assessment of their applications and industrial-scale production (Ingham and Moore, 2007).
The most important prerequisite for these studies is the production of high levels of biologically
active bacteriocin. Although these peptides can be purified from their native producing strains,
the process is time-consuming and laborious, and bacteriocin yields are often low (Rodríguez
et al., 2003). Synthetic production is one alternative in some cases, but the complexity of some
of the bacteriocins and the cost of the process limit the synthesis of large quantities (Chen
et al., 2012). Therefore, attempts to increase the production of bacteriocins using alternative
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hosts such as Lactococcus lactis and other lactic acid bacteria
(LAB) have been investigated (reviewed in Cintas et al., 2011).
These strains, which are food-grade organisms, offer a safer
choice for industrial food products, and provide the genetic and
secretory machinery for efficient LAB bacteriocin production.
However, the expression strains available are highly specific and
the results in terms of yield are still disappointing at industrial
level, restricting the variety and quantity of bacteriocin produced
(Rodríguez et al., 2003). Given these limitations E. coli, the most
commonly used organism for heterologous protein production, is
an attractive option for the heterologous bacteriocin expression
due to its rapid growth on inexpensive media, its extensive
genetic characterization and the availability of versatile cloning
tools, expression systems and strains (Mergulhao et al., 2004;
Rosano and Ceccarelli, 2014; Jia and Jeon, 2016). This could
facilitate the functional characterization and establishment of a
production process in bacteriocins from sources that are difficult
to cultivate, in addition to those bacteriocins discovered by data
mining from sequenced bacterial genomes (Kuo et al., 2013),
increasing their potential for manufacture and commerialization
by food and pharmaceutical industries (Ongey and Neubauer,
2016). However, this approach is not without obstacles which
may arise during the expression, secretion or processing of these
peptides in E. coli (Choi and Lee, 2004).
In order to provide a guide for a design of a successful
expression system for bacteriocin production in this host, the
present review focuses on the different systems currently available
for bacteriocin production in E. coli.
GENERAL CONSIDERATIONS BEFORE
THE EXPRESSION SYSTEM SELECTION
Bacteriocin
The choice of an expression system is not simple. Firstly,
the characteristics of the bacteriocin should be taken into
account, such as the presence of post-translational modifications
and disulfide bonds, because these may affect its heterologous
production.
According to Cotter et al. (2012), LAB bacteriocins are
classified into those which are either post-translationally
modified (class I) and unmodified or minimally modified
peptides (class II). Class I can be subdivided into lantibiotics
(with lanthionine bridges), linaridins, proteusins, linear azole-
or azoline-containing peptides, cyanobactins, thiopeptides,
lasso peptides, sactibiotics (contain sulfur-α-carbon linkages),
bottromycins, glycocins, and modified microcins that do
not belong to other subgroups. Class II is further divided
into class IIa (the pediocin-like bacteriocins), IIb (the two-
peptide bacteriocins), IIc (circular bacteriocins), IId (unmodified,
linear, non-pediocin-like, single-peptide bacteriocins that do not
belong to other subclasses), and IIe (the microcin E492-like
bacteriocins). In this classification, the large (>10 kDa), heat-
labile antimicrobial peptides bacteriolysins (formerly class III
bacteriocins) were removed from the bacteriocin category.
Similarly, bacteriocins from Gram-negative organisms can be
divided into small peptides, such as microcins [class I (presence
of modifications) or II (unmodified)], and large peptides such as
colicins (Drider and Rebuffat, 2011).
Genes Required for Bacteriocin Expression
In general, the production of bacteriocins in the native
host requires several genes including a structural gene that
encodes the prepeptide (or two structural genes for the two
peptide bacteriocins). Other genes encode an immunity protein,
specialized secretion machinery and in many cases proteins
capable of performing modifications and regulatory sequences
(Nes et al., 1996). Therefore, different strategies are required
depending on the characteristics of each bacteriocin to ensure
production (see Table 1).
In most cases, the expression of the structural gene or its
mature sequence is enough to produce the active bacteriocin.
Some examples include carnobacteriocin B2 (Jasniewski et al.,
2008), divercin AS7 and V41(Richard et al., 2004; Ingham
et al., 2005; Yildirim et al., 2007; Olejnik-Schmidt et al., 2014),
epidermicin NI01 (Sandiford and Upton, 2012), gassericin A
(Kawai et al., 2003), or sakacin P (Chen et al., 2012) (see
Table 1). However, the transporter gene is also necessary for the
synthesis of some bacteriocins, for example in the production
of pediocin PA-1 and bactofencin A (Bukhtiyarova et al., 1994;
Mesa-Pereira et al., 2017). In other cases, the co-expression of
the structural gene with the genes involved in post-translational
modifications on the same or different plasmids are required for
the heterologous expression of lantibiotics such as lichenicidin
(Caetano et al., 2011a,b; Kuthning et al., 2015), nukacin ISK-1
(Nagao et al., 2005), prochlorosin, haloduracin, nisin (Shi et al.,
2011), suicin (Wang et al., 2014), and the sactibiotic subtilosin A
(Himes et al., 2016), amongst others.
Toxicity
The potential toxicity to E. coli due to the overexpression of
the mature peptides or components of the secretion machinery
and other bacterial integral membrane proteins (Fath and Kolter,
1993; Miller et al., 1993) must also be considered as these
could interfere with the growth and viability of E. coli, limiting
bacteriocin production (Bentley et al., 1990; Mccormick et al.,
1996; Biet et al., 1998; Gutiérrez et al., 2005; Ingham et al., 2005;
Moon et al., 2005; Masias et al., 2014; Mesa-Pereira et al., 2017).
PLASMIDS FOR BACTERIOCIN
EXPRESSION IN E. COLI
General Features
Expression vectors require various components to carry out their
functions, including; (i) an origin of replication; (ii) a selection
marker (generally genes encoding resistance to antibiotics); (iii)
a promoter region for gene transcription initiation; and (iv)
multiple unique restriction enzyme sites arranged in a polylinker
region after the promoter to facilitate the cloning (referred to
as multiple cloning sites; MCS). In some cases, two or more
MCS are available in commercial plasmids (i.e., Duet vectors
and pRSFDuetTM-1) for cloning several genes of interest without
the need to use multiple plasmids. In addition, the MCS can
additionally provide fusion tags to facilitate the purification of the
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TABLE 1 | Bacteriocins heterologously produced by E. coli.
Bacteriocin Native hosta E. coli strainb Vectorc Locationd Culture conditionse References
Ala(0)actagardine
(Class I, Lantibiotic)
A. garbadinensis ATCC
31049
BL21 (DE3) pRSFDuet-1-garA-garM
pCDFDuet-1-2XgarO
SCF LB, 0.2mM IPTG
20h, 18◦C
Shi et al., 2012
BacR1
(Class II)
Sta. aureus UT0007 BL21 (DE3) pSuV1- bacR1*c M LB, 2mM IPTG
ON, RT
Ingham et al.,
2005
Bactofencin A
(Class IId)
Lb. salivarius DPC6502 Tuner (DE3) pETcoco-2-bfnAbfnI
DLSL0052DLSL0053
M LB, 0.05–0.1mM IPTG
3h, 37◦C
Mesa-Pereira
et al., 2017
Bovicin HJ50
(Class I, Lantibiotic, SS
bond)
Str. bovis HJ50 BL21 (DE3) pET28a-bovAM,
pET28a-bovT150
SCF BovA expression:
LB, 0.5mM IPTG
20h, 18◦C
BovT150 expression:
LB, 0.5mM IPTG
12h, 20◦C
Lin et al., 2011
Str. bovis HJ50 BL21 (DE3) pET28a-bovAM
pACYC-Duet-bovT or
bovT150
SCF LB, 0.5mM IPTG
5, 10, 20 h, 37◦C
Wang et al., 2016
Str. bovis HJ50 C43 (DE3) pET28a-bovAM
pACYC-Duet-bovT or
bovT150
M LB, 0.5mM IPTG
10-20 h, 37◦C
Wang et al., 2016
Carnobacteriocin B2
(Class IIa)
C. piscicola LV17B – pMALc-CbnB2*
pMALc-CbnB2P
TE Rich broth, 0.3mM IPTG
3h, 37◦C
Quadri et al., 1997
C. maltaromaticum
CP5
BL21 (DE3) pET32a-CbnB2* TE TB, 0.55mM IPTG or
14.6mM lactose
3 h, 37◦C
Jasniewski et al.,
2008
Carnobacteriocin BM1
(Class IIa)
C. maltaromaticum
CP5
BL21 (DE3) pET32a-CbnBM1*
pET32a-CbnBM1M41V*
TE TB, 0.55mM IPTG or
14.6mM lactose
3 h, 37◦C
Jasniewski et al.,
2008
ColA-43864
(Colicins)
Cit. freundii ATC43864 S17-1 pMQ124-colA-43864 SCF LB, 0.2% L-arabinose
3 h, 37◦C
Shanks et al.,
2012
Colicin V
(Colicins)
E. coli KS300/pMS421 pHLZ01 (pBR322)- cvaC* TE
(periplasm)
Zhang et al., 1995
Divercin AS7
(Class IIa, two SS bonds)
C. divergens AS7 BL21 (DE3) pLys pET28b-AS7 SCF LB, 0.1mM IPTG
24h, 37◦C
Olejnik-Schmidt
et al., 2014
Divercin V41
(Class IIa)
C. divergens V41 Origami (DE3) pLysS pET32b- DvnV41*c SCF TB, 1mM IPTG
3h, 37◦C
Richard et al.,
2004
C. divergens V41 BL21 (DE3) pSuV1- DivV41*c M SOC, 2mM IPTG
ON, RT
Ingham et al.,
2005
C. divergens V41 Origami (DE3)
pLysS/pCR03
pET32b- DvnV41* SCF TB or M9, 0-2mM IPTG
3h, 30◦C
Yildirim et al., 2007
Divergicin A
(Class IIc)
C. divergens LV13 MC4100/pHk22 pMG36e-Leucocin A
leader-divergicin A
pMG36e-ColV
leader-divergicin A
M YT and 0.2mM
2,2′-dipyridyl.
37◦C
Van Belkum et al.,
1997
C. divergens LV13 BL21 (DE3)/pHk22 pT7-1-Lactococcin A
leader-divergicin A
TE YT and 0.2mM
2,2′-dipyridyl, 0.4mM IPTG
2h, 37◦C
Van Belkum et al.,
1997
E50-52
(Class IIa)
Ent. faecium NRRL
B-30746
BL21 (DE3) pET SUMO-rb50-52 SCF LB, 1.5mM IPTG
5h, 37◦C
Wang et al., 2013
Enterocin A
(Class IIa)
Ent. faecium ATB 197a BL21 (DE3) pET37b-entA TE
SCF
M
LB, 0.1mM IPTG
1-4 h, 37◦C
Klocke et al., 2005
Enterocin B
(Class II)
Ent. faecium ATB 197a BL21 (DE3) pET37b-entB TE LB, 0.1mM IPTG
1–4 h, 37◦C
Klocke et al., 2005
Enterocin CRL35
(Class IIa, one SS bond)
Ent. mundtii CRL35 Rosetta (DE3) pLysS pET22b-munA M LB or M9, 0.5mM IPTG
1h, 37◦C
Masias et al., 2014
Ent. mundtii CRL35 BL21 (DE3) pLysS pET22b-munA M LB, 0.5mM IPTG
1h, 37◦C
Masias et al., 2014
Ent. mundtii CRL35 C41 (DE3) pLysS pET22b-munA M LB, 0.5mM IPTG
1h, 37◦C
Masias et al., 2014
(Continued)
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TABLE 1 | Continued
Bacteriocin Native hosta E. coli strainb Vectorc Locationd Culture conditionse References
Ent. mundtii CRL35 C43 (DE3) pLysS pET22b-munA M LB, 0.5mM IPTG
1h, 37◦C
Masias et al., 2014
Ent. mundtii CRL35 Rosetta –gami 2
(DE3)
pET22b-munA M LB, 0.5mM IPTG
1h, 37◦C
Masias et al., 2014
Ent. mundtii CRL35 Origami (DE3) pET22b-munA M LB, 0.5mM IPTG
1h, 37◦C
Masias et al., 2014
Ent. mundtii CRL35 BL21 (DE3) p8760
(PBAD24)-EtpM-munA
pACYCDuet-1-munC
TE
(membrane)
Ent35:
LB, 0.6% arabinose
5min
MunC:
LB, 0.02% lactose
1 h, 37◦C
Barraza et al.,
2017
Enterocin P
(Class IIa)
Ent. faecium BL21 (DE3) pTYB1-EntP*c M LB, 2mM IPTG
ON, RT
Ingham et al.,
2005
Ent. faecium P13 Tuner (DE3) pLacI pETBlue-1-entP
pETBlue-1-entP-entiP
M
SCF
IB
M9, 0-1mM IPTG
3h, 37◦C
Gutiérrez et al.,
2005
Epidermicin NI01
(Class IId)
Sta. epidermidis 224 BL21 (DE3) pET29a-edcA SCF 2 × YT broth, 0.05mM
IPTG
ON, 17◦C
Sandiford and
Upton, 2012
Gassericin A (class IIc) Lb. gasseri LA39 JM109 PinPoint
Xa-1-gassericinA*
SCF LB, 2 µmol biotin
8 h, 37◦C
Kawai et al., 2003
Haloduracin
(Class I, two-peptide
lantibiotic)
B. halodurans BL21 (DE3) pRSFDUET-1-HalA1-Xa-
HalM1
pRSFDUET-1-HalA2-Xa-
HalM2
SCF LB, 0.5mM IPTG
18h, 18◦C
Shi et al., 2011
Lactococcin G
(Class IIb, two-peptides)
L. lactis LMGT 2081 BL21 RIL (DE3)
pLysS
pGEV-LcnG-α or LcnG-β IB M9, 1mM IPTG
6-8 h, 37◦C
Rogne et al., 2008
Lactococcin K L. lactis MY23 BL21 (DE3) pEMBP- lcnK
pET21c- lcnK
SCF
IB
LB, 1mM IPTG
12h, 37◦C
Kim et al., 2006
Lichenicidin
(Class I, two-peptide
lantibiotic)
B. licheniformis 189 BLic5 pCC2FOSTM- lic operon M Medium M
24h, 37◦C
Caetano et al.,
2011a,b
B. licheniformis 189 BL21 gold (DE3) pRSFDuet-1_TM1A1 and
pRSFDuet-1_TPM2A2
M Medium M, 2 × YT, SB, TB
and LB-Kelly
0.5mM IPTG
24h, 30◦C
Kuthning et al.,
2015
LSEI_2163
(Class IId, one SS bond)
Lb. casei ATCC334 Origami (DE3) pLysS pAB-238- LSEI_2163 TE LB, 1mM IPTG
5h, 37◦C
Kuo et al., 2013
LSEI_2386
(Class II)
Lb. casei ATCC334 Origami (DE3) pLysS pAB-238- LSEI_2386 TE LB, 1mM IPTG
5h, 37◦C
Kuo et al., 2013
Mersadicin
(Class I, Lantibiotic)
B. licheniformis MKU3 M15/pRep4 pQE-30UA-lanA SCF LB, 0.4mM IPTG
4h, 37◦C
Kayalvizhi et al.,
2016
Mesentericin Y105
(Class IIa)
Leu. mesenteroides
Y105
DH5α pBluescript SKII+- dvnA
leader- mesY*-mesI
pBluescript SKII+- dvnA
leader- mesY-mesI
M LB, 1mM IPTG
37◦C
Biet et al., 1998
Microcin B Ps. syringae pv.
glycinea B076
BL21 (DE3) pBAD His/B- mcb SCF M9, 10mM Arabinose
24 h, 30◦C
Metelev et al.,
2013
Nisin
(Class I, Lantibiotic)
L.lactis BL21 (DE3) pRSFDUET-1-nisA- nisB
pACYCDUET-1-nisC
SCF LB, 0.5mM IPTG
15h, 18◦C
Shi et al., 2011
Nukacin ISK-1
(Class I, Lantibiotic)
Sta. warneri ISK-1 BL21 (DE3) pET14b-nukAM SCF 2 xYT, 1mM IPTG
20h, 20◦C or 3 h, 37◦C
Nagao et al., 2005
Pediocin AcH
(Class IIa, two SS bonds)
P. acidilactici H E609L pPR682-pap* M LB, 1mM IPTG
3h, 37◦C
Miller et al., 1998
P. acidilactici LB42-923 JM109 pHPS9- pap operon M LB, 37◦C Bukhtiyarova
et al., 1994
(Continued)
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TABLE 1 | Continued
Bacteriocin Native hosta E. coli strainb Vectorc Locationd Culture conditionse References
Pediocin PA-1
(Class IIa, two SS bonds)
P. acidilactici PAC1.0 V850 pSRQ11- ped operon
pSRQ11.2- ped operon
pBR322- ped operon
M M9 supplemented
with 1% yeast extract and
1% Hy Case
ON, 37◦C
Marugg et al.,
1992
P. acidilactici F DH5α pPC418- ped operon
pHPS9- ped operon
M LB, ON, 37◦C Coderre and
Somkuti, 1999
P. acidilactici BL21 (DE3) pSuV1- PedPA-1*c M LB, 2mM IPTG
ON, RT
Ingham et al.,
2005
P. acidilactici K10 M15/pRep4 PQE-30 Xa-pedA* ET LB, 1mM IPTG
4h, 37◦C
Moon et al., 2005
P. acidilactici K10 M15/pRep4 PQE-40-pedA* ET
IB
LB, 1mM IPTG
4h, 37◦C
Moon et al., 2006
P. acidilactici PAC1.0 Origami (DE3) pET32b- pedA* SCF LB, 0.02mM IPTG
4h, 37◦C
Beaulieu et al.,
2007
P. acidilactici PA003 BL21 (DE3) pET32b- pedA*
pET20b- pedA*
IB
SCF
LB, 0.02mM IPTG
4h, 37◦C
Liu et al., 2011
P. acidilactici LMG2351 Tuner (DE3) pETcoco2-ped operon M LB, 0.05-0.1mM IPTG
3h, 37◦C
Mesa-Pereira
et al., 2017
Piscicolin 126
(Class IIa, one SS bond)
C. piscicola JG126 AD494 (DE3) pET32- pisA* TE LB, 0.1mM IPTG
4h, 37◦C
Gibbs et al., 2004
C. piscicola BL21 (DE3) pSuV1- pisA*c M LB, 2mM IPTG
ON, RT
Ingham et al.,
2005
Plantaricin E
(Class IIb, two-peptide
bacteriocin)
Soil metagenome BL21 (DE3) pET32a-plnE* SCF LB, 1mM IPTG
5h, 16, 25, 30 and 37◦C
Pal and
Srivastava, 2014
Lb. plantarum LR/14 BL21 (DE3) pET32a-plnE,plnG or
plnH.
pET28a-plnE,plnG or
plnH.
SCF
IB (PlnG
and PlnH)
LB, 1mM IPTG
16h, 22◦C
Pal and
Srivastava, 2015a
Soil metagenome BL21 (DE3) pET32a-plnE SCF Small scale: LB, TB
0.5mM IPTG
5 and 9 h at 22◦C
Large scale: 12 L LB
0.5mM IPTG
3h, 25 and 30◦C
Pal and
Srivastava, 2015b
Lb. plantarum 163 BL21 (DE3) pET32a-plnEm* SCF LB, 0.5mM IPTG
8h, 25◦C
Meng et al., 2017
Plantaricin EF
(Class IIb, two-peptide
bacteriocin)
Lb. plantarum C11 BL21 RIL (DE3)
pLysS
pGEV2- plnE
pGEV2- plnF
IB M9, 1mM IPTG
4h, 37◦C
Fimland et al.,
2008
Lb. plantarum BL21 (DE3) pET32a-plnE
pET32a-plnF
SCF LB, 1mM IPTG
6h, 16, 20, 25, 30, 37◦C
Tang et al., 2018
Plantaricin F Soil metagenome BL21 (DE3) pET32a-plnF* SCF LB, 1mM IPTG
5h, 16, 25, 30 and 37◦C
Pal and
Srivastava, 2014
Plantaricin J Soil metagenome BL21 (DE3) pET32a-plnJ* SCF LB, 1mM IPTG
5h, 16, 25, 30 and 37◦C
Pal and
Srivastava, 2014
Plantaricin JK
(Class IIb, two-peptides)
Lb. plantarum C11 BL21 RIL (DE3)
pLysS
pGEV2- plnJ
pGEV2- plnK
IB LB or M9, 1mM IPTG
3-4 h, 37◦C
Rogne et al., 2009
Plantaricin K Soil metagenome BL21 (DE3) pET32a-plnK* SCF LB, 1mM IPTG
5h, 16, 25, 30 and 37◦C
Pal and
Srivastava, 2014
Plantaricin NC8
(Class IIb, two-peptide
bacteriocin)
Lb. plantarum ZJ316 BL21 (DE3) pET32a- PLNC8α
pET32a- PLNC8β
SCF LB
0.1, 0.2, 0.5, 1mM IPTG
5,10,16, 20 h
16, 20, 25, 30 and 37◦C
Jiang et al., 2016
Plantaricin Pln1
(Class II)
Lb. plantarum 163 BL21 (DE3) pET32a-pln1 TE LB
0.5, 1, 2, 4mM IPTG
4, 6, 8, 10 h
20, 25, 30 and 37◦C
Meng et al., 2016
(Continued)
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TABLE 1 | Continued
Bacteriocin Native hosta E. coli strainb Vectorc Locationd Culture conditionse References
Plantaricin S34
(Class II)
Lb. plantarum S34 BL21 (DE3) pLysS pET32a-plnF*
pET32a-plnE*
SCF LB, 0.5mM IPTG
5h, 22◦C
Mustopa et al.,
2016
Prochlorosin 1.7, 2.11
and 3.3 (Class I,
Lantibiotics)
Prochlorococcus BL21 (DE3) pRSFDUET-1-procA-
procM
SCF LB, 0.1mM IPTG
20h, 18◦C
Shi et al., 2011
Pyocin S4 Ps. aeruginosa PAO BL21 (DE3) pLysS pET15b-S4imm SCF LB, 1mM IPTG
ON, 28◦C
Elfarash et al.,
2012
Sakacin P
(class IIa)
Lb. sakei BL21 (DE3) pET28a–sakP* IB LB, 0.8mM IPTG
3h, 20 or 37◦C
Chen et al., 2012
Subtilosin A
(Sactipeptide)
B. subtilis 168 BL21 (DE3)/pPH151 pETDuet-sboA-albA IB LB, 0.5mM IPTG
22–24 h, 18◦C
Himes et al., 2016
Suicin
(Lantibiotic, SS-bond)
Str. suis serotype 2 BL21 (DE3) pET28a-suiAM
pET28a-suiTR
IB LB, 0.5mM IPTG
20h 16◦C
Wang et al., 2014
Warnericin RK
(Class II)
Sta. warneri RK M15/pREP4 pQE30-warc
pQE70-warc
TE LB or M9, 1mM IPTG
6h, 37◦C
Verdon et al., 2013
aNative hosts: A., Actinoplanes; B., Bacillus; C., Carnobacterium; Cit., Citrobacter; E., Escherichia, Ent., Enterococcus; Str., Streptococcus; L., Latococcus; Lb., Lactobacillus; Ps.,
Pseudomonas; Sta., Staphylococcus; P., Pediococcus.
bE. coli strains containing plasmids: pCR03, derivative pET-32 plasmid; pHK22, contains the structural gene and the immunity gene for colicin V as well as the genes encoding the two
inner-membrane transport proteins, CvaA and CvaB, for colicin V; pMS421, pSC101 with lacIQ; pPH151, containing the E. coli suf ABCDSE genes that facilitate the proper assembly
and repair of the Fe– S cluster; pREP4, contains lacI gene for regulating expression from PQE vectors. pLysS and pLacI information is listed in the text.
c*Mature sequence (without leader peptide), ccodon optimized genes.
dLocation: IB, Inclusion bodies; SCF, Soluble Cellular Fraction (soluble fraction after cell pellet sonication); M, culture medium (cell-free supernatants), TE, Total cell extract.
eCulture medium: Luria broth (LB) medium, Terrific broth (TB), 2 × Yeast extract-Tryptone broth (2 × YT). ON, overnight; RT, Room Temperature.
FIGURE 1 | Schematic plasmid map showing the major features present in
common expression vectors.
expressed bacteriocins. Plasmids must also contain one or several
terminators to ensure an efficient transcriptional termination and
prevent the transcription downstream of the coding sequence
of interest (Figure 1). In terms of translational features, the
plasmidmust include a ribosome binding site (RBS) with a Shine-
Dalgarno sequence (UAAGGAGG) located 5–13 bases upstream
of the start codon for the interaction with the 3′ end of rRNA
during translation initiation (reviewed in Mergulhao et al., 2004;
Terpe, 2006; Durani et al., 2012; Rosano and Ceccarelli, 2014).
Plasmid Copy Number
A replicon consists of one origin of replication with associated
control elements and is involved in plasmid replication and copy
number control (del Solar and Espinosa, 2000). The number of
copies per cell can vary between one and approximately one
hundred. Theoretically, the higher the copy number of a plasmid,
the higher the expression of the gene of interest. However, this
often results in aggregation, misfolding or protein degradation in
E. coli (Tolia and Joshua-Tor, 2006), and could also cause cellular
toxicity when the overexpression of secretion machinery and
other integral membrane proteins are required for bacteriocin
production. For this reason, low and middle copy vectors (15–
20 copies per cell) based on ColE1, pMB1 replicons, including
the pBR322 and pET vector systems and pACYC plasmids with
an origin replication derived from p15A, have been successfully
used for bacteriocin expression (Table 2). In addition, the use of
two plasmids with compatible origins (e.g., ColE1 with p15A,
pMB1 with p15A) has allowed for dual expression of proteins
for functional characterization (Table 1). In this regard, the
expression vector pETcoco-2 could be a useful tool for studying
whole operons since it enables the control of copy number by
arabinose induction, facilitating the optimization of bacteriocin
expression (Sektas and Szybalski, 2002; Mesa-Pereira et al., 2017).
Promoter Region
A careful balance of promoter strength and gene copy number
is necessary for the optimization of the bacteriocin expression
level. Since bacteriocins could be toxic for the host, the promoter
strength should be adequate in order to minimize the metabolic
burden on E. coli prior to the production phase and prevent
the saturation of the host transport machinery (Rosenberg, 1998;
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TABLE 2 | Features of expression vectors used for bacteriocin production in E.coli.
Vectora Size (bp) Promoterb Selectionc Tags and fusion partnersd Protease cleavage
sitese
Origin Supplier/References
pAB-238 5,800 T7lac Amp N-Trx Thr pBR322 Kuo et al., 2013
pACYCDuet-1* 4,008 T7lac Cm N-His
S
None P15A Novagen
pBAD His/B 4,100 araBAD Amp N-His EK pUC Invitrogen
pBAD-24 4,542 PBAD Amp None None pBR322 Invitrogen
pBluescript SKII+ 2,961 lac Amp None None pUC Stratagene
pBR322 4,361 None Amp, Tet None None pMB1 NEB
pCC2FOSTM 8,181 T7 Cm None None oriV/oriS Epicentre
Biotechnologies
pCDFDuet-1* 3,781 T7lac Str/Spe N-His
S
None pCloDF13 Novagen
pEMBP T7 Amp MBP EK pBR322 Bioprogen
pETBlue-1 3,476 T7lac Amp C-His None pUC Novagen
pETcoco-2 12,417 T7lac
pBAD
Amp N-His
S
C-HSV tag
EK Mini-F/RK2 Novagen
pETDuet-1 5,420 T7 Amp N-His
S
None pBR322 Novagen
pET SUMO 5,643 T7lac Kan N-His
N-SUMO
SUMO protease pBR322 Invitrogen
pET-14b 4,671 T7 Amp N-His Thr pBR322 Novagen
pET-15b 5,708 T7 Amp N-His Thr pBR322 Novagen
pET-20b (+) 3,716 T7 Amp Signal sequence
C-His
None pBR322 Novagen
pET-21c 5,441 T7lac Amp C-His None pBR322 Novagen
pET-22b (+) 5,493 T7lac Amp Signal sequence
C-His
None pBR322 Novagen
pET-28a,b 5,369 T7lac Kan N-His
C- His
Thr pBR322 Novagen
pET-29a 5,371 T7lac Kan C-His
Stag
Thr pBR322 Novagen
pET-32a,b 5,900 T7lac Amp N-Trx
Internal His
C-His
Thr
EK
pBR322 Novagen
pET-37b (+) – T7lac Kan Signal sequence
N-CBDcenA
C-His
Thr
Xa
pBR322 Novagen
pGEV2 >5,443 T7lac Amp N-GB1 domain
C-His
Thr
Xa
pBR322 Huth et al., 1997
PinPoint 3,331 T7 or tac Amp Biotin Xa ColE1 Promega
pHPS9** 5,700 P59 Em Cm None None pMB1
pTA1060
ATCC
pMG36e 3,700 P32 Em None None pWV01 van de Guchte et al.,
1989
pMQ124 7,621 PBAD Gm None None ColE1/pRO1600 Shanks et al., 2009
pPC418** 9,135 STP2201 Amp Em None None – Coderre and Somkuti,
1999
pPR682
(pMAL-c2x)
6,645 tac Amp N-MBP Xa ColE1 NEB
pQE-30UA 3,504 T5lac Amp N-His None ColE1 Quiagen
pQE-30 Xa 3,500 T5lac Amp N-His Xa ColE1 Quiagen
pQE-40 4,031 T5lac Amp N-His
N-DHFR
None ColE1 Quiagen
PQE-70 3,426 T5lac Amp C-His None ColE1 Quiagen
pRSFDuet-1* 3,829 T7lac Kan N-His
S
None RSF1030 (NTP1) Novagen
(Continued)
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TABLE 2 | Continued
Vectora Size (bp) Promoterb Selectionc Tags and fusion partnersd Protease cleavage
sitese
Origin Supplier/References
pT7-1 2,400 T7 Amp None None ColE1 Tabor and Richardson,
1985
pTYB12 7,417 T7 Amp N-VMA intein CBD None pBR322 NEB
pSRQ11*** 9,400 – Em – None – Gonzalez and Kunka,
1987
pSuV1 7,332 T7 Amp pelB signal sequence
C-VMA intein CBD
Self-cleavage ColE1 Ingham et al., 2005
a*Vectors containing two MCS (Multiple Cloning Site). **Shuttle vectors: pHPS9 E.coli-Bacillus subtilis shutle vector; pPC418, E. coli–St. thermophiles shuttle vector. ***pSRQ11 PA-1
pediocin plasmid.
bPromoters information is listed in the text. constitutive p32 and p59 promoter from L. lactis subsp. cremoris Wg2, STP2201 promoter from S. thermophilus ST128.
cAntibiotic resistance markers: Amp, ampicillin; Cm, chloramphenicol; Em, erythromycin; Gm, gentamicin; Kan, kanamycin; Tet, tetracycline; Str, streptomycin; Spe, spectinomycin.
dCBD, chitin binding domain; DHFR, Dehydrofolate reductase; GB1 domain: immunoglobulin- DNA binding domain of streptococcal protein G.
eEK, enterokinase; Thr, thrombin.
Mergulhão et al., 2003; Mergulhao et al., 2004). This might
explain the failure to generate successful expression plasmids
under the control of constitutive promoters (Mccormick et al.,
1998; McCormick et al., 1999), while the use of inducible
promoters enables stable bacteriocin expression (Gutiérrez et al.,
2005). Thus, an appropriate promoter must be strong, have
a low basal expression level (i.e., be highly repressible) and a
cost-effective induction system.
A large number of promoter systems have been described for
protein production in E. coli (reviewed in Terpe, 2006; Durani
et al., 2012; Rosano and Ceccarelli, 2014). In terms of bacteriocin
expression, the L-arabinose inducible araBAD (PBAD) promoter
has been used in some studies (Shanks et al., 2012; Metelev et al.,
2013; Barraza et al., 2017), while most bacteriocins have been
expressed using lac-derived promoters inducible by lactose or its
non-hydrolyzable analog isopropyl β-D-thiogalactopyranoside
(IPTG), including tac promoter (Miller et al., 1998; Kawai et al.,
2003), T5lac (Moon et al., 2005, 2006; Verdon et al., 2013;
Kayalvizhi et al., 2016) and the most widely used T7 and T7lac
promoters (Table 2).
In T7 promoter systems, the gene of interest is cloned behind
a promoter recognized by the phage T7 RNA polymerase that
is provided by another plasmid or in the bacterial genome
in a prophage (λDE3). T7 RNA polymerase is under the
transcriptional control of a lacUV5 promoter inducible by lactose
or IPTG. Basal expression can be controlled by the introduction
of amutated promoter of the lacI gene, called lacIQ, that increases
the expression of the lac promoter repressor LacI. Additionally,
the co-expression of T7 lysozyme provided in a compatible
plasmid (pLysS or pLysE) can inhibit the transcription of T7
RNA polymerase. In the case of the T7lac promoter, this also
includes a lacO operator downstream of the promoter that
avoids basal expression (reviewed in Rosano and Ceccarelli,
2014).
Protein Targeting-Signal Secretion
Sequences
Since E. coli is a Gram-negative bacterium, bacteriocin
production can be confined to the cytoplasm where it can
accumulate in a soluble form or aggregate in insoluble inclusion
bodies, or can also be secreted into the periplasmic space or
into the culture medium. Several factors including protein size,
amino acid composition, and the type of leader peptide can
affect bacteriocin translocation to these locations (reviewed in
Mergulhao et al., 2004).
Most bacteriocins use a dedicated secretion machinery in
their natural hosts to export the bacteriocin to the extracellular
media. However, the production of active bacteriocins directly
to the culture medium by cloning their whole operons in E. coli
has been reported on a limited number of occasions (Figure 2)
(Caetano et al., 2011a; Mesa-Pereira et al., 2017). Generally,
the overexpression of cloned native genes leads to bacteriocin
accumulation in inclusion bodies in the cytoplasm. At first
glance, the formation of inclusion bodies could be advantageous
as the expressed bacteriocins are inactive and protected against
host proteases, facilitating their purification and a high protein
yield. However, this aggregation can affect the host metabolism
and additional steps (inclusion body isolation, solubilization of
the aggregates, and protein refolding) are required for their
purification, limiting their large-scale production (Mergulhao
et al., 2004).
The processing and the correct folding of bacteriocins as
well as their recovery can be simplified when the peptide is
secreted into the E. coli periplasm or into the culture medium.
To achieve that, signal sequences of proteins recognized by a
general protein secretory pathway (sec pathway), such as the
maltose-binding protein malE (Miller et al., 1998), the pectase
lyase secretion signal pelB (Ingham et al., 2005), and the outer
membrane protein ompA (Zhang et al., 1995), have been fused
to the bacteriocin sequence for targeting their secretion to the
periplasm. In addition, the bacteriocin divergicin A signal peptide
has been used to direct the expression of mesentericin Y105 in
E. coli in the absence of their dedicated secretion machinery
(Biet et al., 1998). This relies on the fact that divergicin A,
as well as other bacteriocins such as hiracin JM79 (Sánchez
et al., 2007), acidocin B (Leer et al., 1995), and enterocin P
(Cintas et al., 1997; Gutiérrez et al., 2005), can be exported
by the E. coli sec pathway. Subsequently, the peptides can be
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FIGURE 2 | Bacteriocin activity of 2-fold serial dilutions of cell-free supernatants. Antimicrobial activity of bactofencin A against Lb. bulgaricus LMG 6901 produced by
Lb. salivarius DPC6502 (natural producer) and E. coli Tuner (DE3) carrying the vector expressing the whole bactofencin A operon (bfn) and pediocin PA-1 against
Listeria innocua DPC3572 produced by P. acidilactici LMG2351 (natural producer) or by E. coli Tuner (DE3) carrying the plasmid with the pediocin PA-1 operon (ped).
secreted into the culture medium by osmotic shock or cell wall
permeabilization or, alternatively, be released directly into the
medium using a periplasmic leaky E. coli host (E609L, Miller
et al., 1998).
It is important to mention that bacteriocins containing
disulfide bonds are normally accumulated in the periplasmwhere
disulfide binding proteins catalyze the oxidation process (Miller
et al., 1998) or alternatively overexpressed in the cytoplasm by
thioreductase-deficient (trxB) and glutathione reductase (gor)
deficient strains (Terpe, 2006).
Affinity Tags and Other Fusion Partners
Given the small size of bacteriocins, the incorporation of affinity
tags, such as poly-His-tags, facilitates their detection and allows
for one-step affinity purification. In addition, the use of fusion
protein partners can increase the expression level, enhance
protein solubility and assist in correct folding and disulfide bond
formation (Ingham and Moore, 2007). Common fusion partners
used for bacteriocin production include the cellulose binding
domain (CBDcenA) (Klocke et al., 2005), maltose-binding protein
(MBP) (Quadri et al., 1997; Kim et al., 2006), thiorredoxin (Trx)
(Gibbs et al., 2004; Richard et al., 2004; Beaulieu et al., 2007;
Yildirim et al., 2007; Jasniewski et al., 2008; Caetano et al., 2011a;
Liu et al., 2011; Pal and Srivastava, 2014, 2015a,b; Jiang et al.,
2016; Mustopa et al., 2016; Meng et al., 2017; Tang et al., 2018)
and the small ubiquitin-related modifier SUMO (Wang et al.,
2013).
Since secretion in the native hosts involves the cleavage of
the signal sequence, such fusions often lack antimicrobial activity
until chemical (e.g., cyanogen bromide cleaves proteins on the
C-terminal side of methionine residues) or enymatic cleavage
occurs. The cyanogen bromide (CNBr) chemical cleavage
strategy has been used to release the mature PlnE and PlnF
(Fimland et al., 2008) and PlnJ and PlnK (Rogne et al., 2009),
as has also been described for production of carnobacteriocin
B2 and BM1 (Jasniewski et al., 2008) and piscicolin 126 (Gibbs
et al., 2004). However, the most common approach to release
recombinant bacteriocins is to include a sequence, between the
signal peptide and the bacteriocin, recognized by Factor Xa
(Quadri et al., 1997; Kawai et al., 2003; Klocke et al., 2005;
Moon et al., 2006; Ingham and Moore, 2007; Rogne et al., 2008;
Shi et al., 2011), trypsin (Shi et al., 2012; Himes et al., 2016),
thrombin (Klocke et al., 2005), enterokinases (Beaulieu et al.,
2007; Jasniewski et al., 2008; Liu et al., 2011; Pal and Srivastava,
2014, 2015a,b; Jiang et al., 2016; Meng et al., 2016; Tang et al.,
2018), and SUMO proteases (Wang et al., 2013). Alternatively,
the use of intein fusions has been described for the cloning
and expression of self-cleaving fusion forms of unmodified
bacteriocins under appropriate buffer conditions (Ingham et al.,
2005).
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E. COLI STRAINS FOR BACTERIOCIN
EXPRESSION
Since bacteriocins can easily be degraded in the expression strain
(Chen et al., 2012), E. coli BL21 (DE3) and its derivates are
most frequently used for bacteriocin expression (Tables 1, 3) as
they are deficient in the Lon protease and the outer membrane
protease OmpT (Gottesman, 1996). TunerTM (DE3) strains
(Novagen) are lacZY deletion mutants of BL21. The lac permease
mutation (lacY) allows uniform entry of IPTG into all cells
in the population, which enables the regulation of the levels
of protein expression by adjusting the concentration of the
inductor IPTG. Other B related strains such as C41 (DE3)
and C43 (DE3), described specially for the production of toxic
proteins (Terpe, 2006), have been used successfully for the
expression of the bacteriocin bovicin HJ50 while the use of
E. coli BL21 (DE3) did not produce this peptide (Wang et al.,
2016).
The designation DE3 indicates that the host is a lysogen
of λDE3 which carries a chromosomal copy of the T7
RNA polymerase under the lacUV5 promoter required for
the expression of genes under a T7 promoter (Rosano and
Ceccarelli, 2014). To suppress the basal expression of T7 RNA
polymerase prior to induction, especially important for toxic
protein expression that affect cell growth and viability of the
host, pLysS hosts carry a plasmid that encodes the T7 lysozyme,
an inhibitor of T7 RNA polymerase. The pLacI designation
is given to hosts bearing a plasmid that encodes the lac
repressor.
K-12 derivatives have also been used for bacteriocin
expression. E. coli JM109, which is lon protease deficient, has been
used for gassericin A expression (Kawai et al., 2003). Divercin
V41, enterocin CRL35, LSE_2163 and LSE_2386 and pediocin
PA-1 that require disulphide bond formation for proper folding
have been expressed in OrigamiTM (DE3) strains (Beaulieu et al.,
2007; Yildirim et al., 2007; Kuo et al., 2013; Masias et al.,
2014), which carry a double mutation in thioredoxin reductase
(trxB) and glutathione reductase (gor) genes with an oxidative
cytoplasmic environment that allows disulfide bond formation.
The same trxB/gor mutations are carried by a derived TunerTM
strain, Origami B, combining the characteristics of BL21 and
Origami hosts in one strain (Novagen). Other combinations,
including Rosetta-gamiTM (K-12 derivative) and Rosetta-gamiTM
B (BL21 derivative), facilitate the expression of eukaryotic
proteins containing rare codons and cytoplasmic disulphide
bond formation at the same time. Table 3 summarizes the
features of commercial E. coli strains most used for bacteriocin
production.
TABLE 3 | Features of commercial E. coli strains commonly used for bacteriocin expression.
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AD494 (DE3) K12 • • Kan N
BL21 B • • • N
BL21 (DE3) B • • • N
BL21 gold (DE3) B • • • Tet AT
BL21 (DE3) pLys B • • • • Cam N
BL21 (DE3) RIL (DE3) pLysS B • • • • • Cam S
C41 (DE3) pLysS B • • • • • Cam L
C43 (DE3) pLysS B • • • • • Cam L
ER2566 K12 • • • NEB
M15[pRep4] K12 • Kan Q
Origami (DE3) K12 • • • Cam, Kan, Str, Tet N
Origami (DE3) pLysS K12 • • • • Cam, Kan, Tet N
Rosetta (DE3) pLysS B • • • • • • Cam N
Rosetta-gami 2 (DE3) K12 • • • • Cam, Str, Tet N
Tuner (DE3) B • • • • N
Tuner (DE3) pLacI B • • • • • Cam N
lacIq (constitutive expression of the lac repressor), ompT− (mutation in outer-membrane protease), lon− (Inactivation of Lon protease), trxB− (mutation in thioredoxin reductase),
gor−(mutation in gluthatione reductase), lacY− (lactose permease activity abolished), pLysS (encodes T7 lysozyme), pLacI (encodes lac repressor), dcm−(blocks cytosine methylation).
Toxic proteins include many membrane proteins, some cytoplasmic proteins, and nucleases.
aGold: provide increased transformation efficiency and produce high-quality miniprep DNA. RIL contain extra copies of the argU, ileY, and leuW TRNA genes.
bAntibiotic resistance: Cam, chloramphenicol; Kan, kanamycine; Tet, Tetracycline; Str, Streptomycin.
cSupplier: AT, Agilent Technologies; L, Lucigen; N, Novagen; NEB, New England Biolabs, Q, Quiagen, B, Stratagene.
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Codon Bias
Major differences between the codon usage of E. coli and
the overexpressed protein may be an obstacle for bacteriocin
production, especially in the case of rare codons. Rare codons
are defined as codons used by E. coli at a frequency <1% (Kane,
1995), whichmeans the tRNA for these codons are rare or lacking
in the expression host. To overcome this problem, two strategies
have been used: codon optimization of the mature sequences of
bacteriocins (Richard et al., 2004; Ingham et al., 2005; Verdon
et al., 2013) or increasing the availability of underrepresented
tRNAs by supplying pRIL or pRARE plasmids. pRIL vector
provides extra genes for the tRNAs for Arg (AGG/AGA), Ile
(AUA), and Leu (CUA) while pRARE encodes tRNA genes for
all the above-mentioned codons plus Gly (GGA) and Pro (CCC).
pRIL or pRARE plasmids are supplied in the BL21 derivatives,
BL21 (DE3) Codon Plus strain (Stratagene), and Rosetta (DE3)
strains (Novagen), respectively. However, it is important to
mention that although these strains can improve the level of
production, they sometimes can cause a decrease in protein
solubility (Rosano and Ceccarelli, 2014) or even decrease the
growth rate of E. coli significantly (Masias et al., 2014).
Selecting a Suitable E. coli Strain
Given that the expression level of bacteriocins can vary in
different E. coli strains (Figure 3), it is recommended to test
different strains, chosen to reflect the properties of the bacteriocin
(e.g., disulfide bonds, rare codons, etc.) to select the best host
for the heterologous expression. A clear example is described
by Masias et al. (2014), who showed the expression of enterocin
CRL35 in E. coli BL21, C41, C43, Origami, and Rosetta-gami 2.
In this study, the expression of enterocin CRL35 was lower in
E. coli C41 and C43 than in other E. coli strains. The best strains
for enterocin CRL35 expression were E. coli Rosetta and E. coli
Rosetta-gami 2 since they are able to synthesize proteins despite
the presence of rare codons. In addition, this study showed
that E. coli Rosetta produced an additional enterocin CRL35
variant. Therefore, the correct choice of the strain is critical for
bacteriocin expression.
CULTURE CONDITIONS FOR
BACTERIOCIN EXPRESSION
Both culture media composition and culture conditions are
important for optimizing the heterologous expression of
bacteriocins and must be optimized for each bacteriocin in each
expression system as reviewed in Table 1. Even two peptides
of the same bacteriocin might require different conditions, for
example the maximum soluble fraction of PLNC8α was observed
under 0.5mM IPTG induction for 16 h at 20◦C, while for
PLNC8β it was 0.2mM IPTG for 20 h at 16◦C (Jiang et al.,
2016). Bacteriocin production can be also increased with different
production strategies such as batch and fed-batch cultivation
(Gibbs et al., 2004; Yildirim et al., 2007). Although it is hard
to generalize, there are some observations that can be taken
into account in terms of culture conditions to facilitate this
trial-and-error process.
FIGURE 3 | Differences in antimicrobial activity of cell-free supernatants (SN)
and lysates (L) of E. coli TunerTM (DE3) and RosettaTM (DE3) cells carrying the
plasmid encoding the whole operon of pediocin PA-1 without induction (−)
and after 3 h of 25µM IPTG induction (+).
Growth Media
Luria Broth (LB) is the most commonly used medium for
culturing E. coli for bacteriocin expression as it is easy to
make and it is nutritionally rich. However, the cell density
obtained with this medium is low, affecting bacteriocin yield.
To overcome this problem, there are media superior to LB
available for reaching higher cell densities such as 2 × yeast
extract tryptone (YT), Terrific Broth (TB), and Super Broth (SB)
(Rosano and Ceccarelli, 2014). 2× YTmedium has been used for
expression of nukacin ISK-1 (Nagao et al., 2005) and epidermicin
NI01 (Sandiford and Upton, 2012), while TB has been used for
divercin V41 (Richard et al., 2004), carnobacteriocin Cbn1 and
CbnB2 production (Jasniewski et al., 2008). Other bacteriocins
have been produced using minimal medium (Rogne et al.,
2008; Metelev et al., 2013). Therefore, there are no general
rules. Pal and Srivastava (2015b) found higher Plantaricin E
yield in LB than in TB, while Kuthning et al. (2015) found
the best-producing conditions for Bliα and Bliβ lichenicidin
peptides was medium M compared to 2 × YT, SB, TB, and
LB-Kelly.
Alternatively, M9 medium supplementation with 10mM of
EDTA and 0.05% Tween 20 at the time of induction could
also increase the final yield (Masias et al., 2014). In addition,
the pH of the culturing media has also an impact on peptide
yields either promoting bacteriocin expression or increasing
peptide stability as described for lichenicidin expression which
increased at pH 6.5 compared to pH 8 (Kuthning et al.,
2015).
Inducer Agents
Bacteriocin expression levels can be tuned by varying the inducer
concentration (Gutiérrez et al., 2005; Yildirim et al., 2007; Masias
et al., 2014; Jiang et al., 2016), but use of a high concentration to
fully induce the promoter does not necessarily lead to maximal
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expression due to the metabolic burden and toxicity of the
inducer to the cells (Glick, 1995).
Although the IPTG inducible lac expression system of E. coli is
the most used for bacteriocin expression, IPTG is expensive and
toxic and therefore not suitable for large-scale production. This
problem could be solved by replacing IPTG by lactose, which is
not toxic, and has resulted in an increase in the production yield
of some bacteriocins such as the carnobacteriocins Cbn BM1 and
Cbn B2 (Jasniewski et al., 2008).
Temperature
Temperature is one of the most important factors for the
expression of functional proteins (Sambrook and Russell, 2001).
Chen et al. (2012) showed that the expression level of sakacin
P was higher when E. coli BL21 (DE3) carrying pET28a-sakP
was induced at 20◦C than at 37◦C. Similar results were observed
when the expression of plantaricin E was induced at 25◦C
rather than at 37◦C (Pal and Srivastava, 2015b). Although
the optimum growth temperature for E. coli is around 37◦C,
the cell growth and the protein synthesis are slowed down at
lower temperatures, which provides the peptides the time and
optimal environment to fold into their native conformation
(Sambrook and Russell, 2001; Peng et al., 2004), decreasing the
aggregation and increasing the expression of soluble protein.
In addition, lowering the temperature, in combination with
the time after induction, might shift the codon usage bias in
E. coli sufficiently to solve some codon-usage based expression
problems (Terpe, 2006). Therefore, it is essential to determine
the optimal induction temperature in each case to improve
the amount of the soluble fraction. When inclusion bodies
formation is a problem, it is recommended to express the
protein in the range of 15–25◦C (Rosano and Ceccarelli,
2014).
CONCLUSION
The development of heterologous expression systems to improve
bacteriocin yield may facilitate their characterization and
broaden their applications in food and pharmaceutical industries.
Currently E. coli is the most popular recombinant protein
expression platform. However, choosing the perfect combination
of expression vector and strain for bacteriocin production in
E. coli is not possible a priori due to the many variables
that can affect bacteriocin production. This review covers
different strategies used for the bacteriocin expression in E. coli
to help the process of choosing the best expression system
and the conditions for any particular bacteriocin with a view
to producing bacteriocins economically for both food and
pharmaceutical applications.
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